Viewing Study NCT03142334


Ignite Creation Date: 2025-12-25 @ 2:25 AM
Ignite Modification Date: 2026-01-12 @ 2:49 PM
Study NCT ID: NCT03142334
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-11-13
First Post: 2017-05-03
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Sponsor: Merck Sharp & Dohme LLC
Organization: